Characteristic markers of inflammation and lipid profile in patients with single-vessel and multivessel coronary artery disease

2015 ◽  
Vol 241 (1) ◽  
pp. e149
Author(s):  
N. Musikhina ◽  
T. Petelina ◽  
L. Gapon ◽  
A. Takkand ◽  
I. Osipova ◽  
...  
2019 ◽  
Vol 26 (2) ◽  
Author(s):  
Iryna Kupnovytska ◽  
Nelia Romanyshyn

         The objective of the research was to study myocardial hemodynamics and contractility, as well as N-terminal pro-brain natriuretic peptide secretion in the patients with chronic coronary artery disease depending on affected coronary artery number according to coronary angiography.          Materials and methods. The study included 62 patients with chronic coronary artery disease, heart failure with preserved left ventricular ejection fraction. Among the examined patients, males prevailed – 52 (83.9%) individuals. The average age was 61.2±1.2 years. The control group included 15 apparently healthy individuals with preserved gender and age proportions. The patients were randomized by the number of the affected coronary arteries and divided into 2 subgroups according to the results of coronary angiography. Subgroup I included 16 (25.8%) patients with single-vessel coronary artery disease; subgroup II comprised 46 (74.2%) patients with multivessel coronary artery disease.           Results and discussion. According to Holter monitoring, average and maximum heart rate, extrasystoles and episodes of ST-segment depression/elevation were more often found in the patients with multivessel coronary artery disease (p<0.05). According to echocardioscopy, in the patients with coronary artery disease regardless of affected coronary artery number, hemodynamic indicators were higher as compared to healthy individuals (p<0.001), while left ventricular ejection fraction was lower in the patients with multivessel coronary artery disease (р<0.001). Serum level of N-terminal pro-brain natriuretic peptide exceeded reference value in both single-vessel coronary artery disease and multivessel coronary artery disease (р<0.001); however, the secretion of this peptide increased in multivessel coronary artery disease (р<0.05). There was observed a strong inverse correlation between left ventricular ejection fraction and N-terminal pro-brain natriuretic peptide in the patients with multivessel coronary artery disease and a moderate correlation in the patients with single-vessel coronary artery disease.          Conclusions. The nature and severity of coronary artery disease clinical course are associated with the number of the coronary arteries affected by atherosclerotic plaques. In multivessel coronary artery disease, according to the results of clinical, functional and laboratory studies, there was observed persistent progression of coronary artery disease and, consequently, chronic heart failure that is the reason for the improvement of schemata for successful treatment of the disease.


2019 ◽  
Vol 40 (Supplement_1) ◽  
Author(s):  
K D Rizas ◽  
L Gross ◽  
D Trenk ◽  
A Komocsi ◽  
M Baylacher ◽  
...  

Abstract Background The TROPICAL-ACS trial showed that platelet function testing (PFT) guided de-escalation of P2Y12-inhibitor is a safe alternative treatment strategy in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI). No specific data are available on the efficacy of this strategy in patients with multivessel coronary artery disease (CAD). Purpose To investigate the safety and efficacy of guided de-escalation of P2Y12-inhibitor treatment in patients with multivessel CAD. Methods Two-thousand six-hundred-two biomarker-positive ACS patients were 1:1 randomized to either conventional treatment with prasugrel for 12 months (control group) or to a PFT guided de-escalation treatment strategy (guided de-escalation group). The primary endpoint (net clinical benefit) was defined as the composite of cardiovascular mortality (CVM), myocardial infarction (MI), stroke, and clinically overt bleeding (bleeding ≥ grade 2 according to the BARC criteria). The ischemic endpoint was defined as the composite of CVM, MI or stroke. We used log-rank statistics and Cox regression analysis with interaction testing to assess the effect of multivessel CAD on the primary and ischemic endpoints. Results Patients with multivessel (n=709) versus single-vessel CAD (n=1,901) exhibited a higher risk for the primary endpoint (10.2% vs. 7.6%; HR 1.36; 95% CI 1.02–1.81; p=0.034). Guided de-escalation was non-inferior to conventional treatment for the primary endpoint in both patients with single-vessel CAD (6.7% vs. 8.5%; pnon-inferiority = 0.001; Figure 1A) and multivessel CAD (9,5% vs. 10.9%; pnon-inferiority=0.041; Figure 1B). Moreover, there was no significant interaction in the prognostic value of guided de-escalation between single-vessel and multivessel CAD for both the primary (HR 0.78 [0.56–1.08]; p=0.137 in patients with single-vessel CAD vs. 0.86 [0.54–1.37; p=0.524 in patients with multivessel CAD; pinteraction=0.732) and combined ischemic endpoints (HR 0.80 [0.44–1.45]; p=0.456 in patients with single-vessel CAD vs. 0.71 [0.35–1. 46]; p=0.356 in patients with multivessel CAD; pinteraction=0.823). Kaplan-Meier curves Conclusion A guided de-escalation of P2Y12-inhibitor appears to be safe and effective in ACS patients with both single-vessel and multivessel CAD. Acknowledgement/Funding Klinikum der Universität München, Roche Diagnostics, Eli Lilly, and Daiichi Sankyo.


Sign in / Sign up

Export Citation Format

Share Document